Total endoscopic sutureless aortic valve replacement: rationale, development, perspectives

Marco Vola¹, Jean-Francois Fuzellier¹, Salvatore Campisi¹, Daniel Grinberg¹, Jean-Noël Albertini¹, Jerôme Morel², Antoine Gerbay¹

¹Cardiovascular Diseases Department, ²Anesthesiology and Reanimation Department, University of St-Etienne, St-Etienne, France

Correspondence to: Marco Vola, MD, PhD. Cardiovascular Surgery Unit, St-Etienne University Hospital, 42055 France. Email: marco.vola@univ-st-etienne.fr.

Transcatheter valve implantation is progressively becoming the first line option for high risk patients in the management of severe aortic valve stenosis. Surgery is likely to remain the gold standard treatment option for intermediate risk patients since it ensures ablation of the underlying pathology and the calcified aortic valvular tissue, which potentially can act as a nidus of chronic embolization and provoke neurocognitive dysfunction in this subset of active patients. The surgical approach is continually evolving, with sutureless technology having the potential to facilitate ministernotomy and minithoracotomy approaches. Furthermore, Nitinol stented models can be introduced through thoracoscopic trocars, enabling the evolution of totally endoscopic aortic valve replacement (TEAVR). We present herein the development of TEAVR, starting from the cadaver experience in our lab. We transitioned through a clinical minithoracotomy video-assisted experience until we finally could initiate a program of human sutureless TEAVR. The limitations of this approach, which is still in refinement, and possible innovative solutions in order to build up a quick and reproducible procedure are discussed.

Keywords: Aortic valve stenosis; minimally invasive surgery; endoscopic surgery; transcatheter aortic valve implantation (TAVI); totally endoscopic aortic valve replacement (TEAVR)

Submitted Jul 04, 2014. Accepted for publication Sep 20, 2014.
doi: 10.3978/j.issn.2225-319X.2014.11.04

View this article at: http://dx.doi.org/10.3978/j.issn.2225-319X.2014.11.04

Introduction

The balance between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) is definitely evolving towards the choice of the transcatheter option for high-risk patients (1). Indeed, there will soon be debate regarding the technique of choice for intermediate-risk patients and focus on the pivotal question “will we still have to ablate the underlying pathology?”. The value of aortic tissue ablation still appears to be fundamental, and the answer remains strictly surgical until safe transcatheter decalcificators become available. The issue is addressed for several reasons: calcium still acts as a generator of paravalvular leakages (PVL) and major adverse cardiovascular events (MACE) during TAVI, relative to calcium scores and distribution (2). Despite encouraging preliminary improvements reported with new generation TAVI valves (3,4), the most serious concern for transcatheter-based therapy is related to post-procedural neurological injury. In fact, the incidence of apparent stroke occurs twice as frequently with TAVI than with SAVR. TAVI does not remove valvular tissues and hence may result in persistence of a valvular source of embolization. When compressed against the aortic wall, this may potentially act as a nidus for calcified emboli, followed by potential deterioration of neurocognitive dysfunction and quality of life (5).

SAVR is continually evolving with minimal access procedures becoming more widespread thanks to the latest turning point: sutureless technology. Beyond the advantages linked to the elimination of sutures and knots (6,7), some of those devices carrying a Nitinol frame offer the possibility of being compressed, enabling their passage through a thoracoscopic trocar.

Total endoscopic aortic valve replacement (TEAVR) aims
to further reduce surgical wall chest trauma by avoiding sternal fractures or costal spreading. Clinical advantages have already been shown during atrial septal defect (ASD) closure surgery (8), thus favoring total endoscopic approach over ministernotomy and minithoracotomy.

Before proceeding to a clinical experience of TEAVR, proof of concept was achieved in cadavers (Figure 1) with the use of a five trocars setting (two working ports, a camera trocar, and two trocars for the management of a pulmonary vent) as previously described (9). The real challenge was to define a step-by-step sequence to deliver the Medtronic 3f Enable bioprosthetic sutureless valve under exclusive control of a camera. From November 2012 to April 2013 thirteen patients received a 3f Enable valve through a video-assisted mini-thoracotomy technique, consisting of keeping the valve compressed with a Prolene stitch in the cuff and cutting it when the valve was visualized with the camera at the proper level for expansion (Figure 2). In our protocol, this delivery technique (10), if successful after a feasibility phase, would be transferred in a close chest setting. The results of the first 13 patients treated through video-assisted procedure were satisfactory, with median cross-clamping time of 64 (range, 37-120) minutes, CPB time of 92 (range, 69-125) minutes and absence of PVL or block.

In this initial phase of TEAVR, patients were strongly selected based firstly on anatomical requirements. Suitable patients should have a sufficiently long intrapericardial ascending aorta in order to keep a comfortable distance between the aortic clamp, the cardioplegia needle, and the aortotomy. Consequently safe placement of the aortic closing sutures is facilitated. We selected patients with a central line of the ascending aorta longer than 5 cm. A second criterion of selection was the presence of a sufficient peri-aortic working space (>2 cm between the inferior margin of the sternum and the aortic anterior wall) to enable the management of the minimally invasive needle holder and grasper during the ascending aorta running suture. Finally, the central axis of the proximal aortic root, together with the operative axis of the third intercostal space, should not create an angle >45° at the center of the aortic valve. Not abiding to this criterion would result in an excessive traction of instruments over margins of the aortotomy. Secondly, patient selection was dependent upon preoperative ventricular ejection fraction to be superior to 45% because of the longer duration of clamping time required. Finally, hemodynamic iliac and femoral artery stenoses have to be excluded.

Between June and December 2013, five patients were selected according to the previous criteria for a TEAVR Enable implantation. All procedures were technically
successful; nevertheless one conversion to second space  
minithoracotomy was necessary after positioning of  
the valve. In this particular patient, the aortotomy was  
performed too proximally in order to achieve a safe  
endoscopic closure within a reasonable cross-clamping  
time; the minithoracotomy was performed with an incision  
connecting the second space working trocar and the optics  
trocar, in order to close the aorta under direct view. The  
overall median clamping and CPB time were 116 (range,  
77-124) and 164 (range, 116-181) minutes, respectively. All  
patients could be extubated within 24 hours. Intraoperative  
and post-operative echography controls excluded presence  
of PVL. No pacemaker implantations were required, and all  
patients left the unit at postoperative day seven.

TEAVR seems to be safe but reserved to selected  
patients according to anatomical criteria and tolerance for  
longer operative durations. With respect to operative times,  
the technique must be improved to become reproducible.  
Catherine Otto, Co-Chair of the writing committee for  
the new ACC/AHA valve guidelines recently stated that if  
larger studies would show that this approach to aortic valve  
replacement is effective with an acceptable mortality and  
morbidity, it would offer an intermediate option between  
standard SAVR and TAVI (11).

**Perspectives**

The evolution of minimally invasive aortic valve surgery  
is linked to the development of technologies such as  
sutureless valves, especially in severe aortic stenosis  
pathology. Compared to minimally invasive mitral valve  
surgery, the possibility of performing a thoracoscopic  
procedure with a cross clamp time comparable with  
conventional surgery is more likely because of the  
different nature of the two pathologies. Most mitral valves  
are surgically repaired, with variable outcomes and a  
reconstruction that can be complex and require sutures,  
while aortic valve stenosis requires a more constant action:  
ablation of tissues, calibration, and valve implantation.  
The nature of the latter is more suitable for a potential
“device-dependent”, rather than operator dependent, procedure that can be performed reliably. It relies on the development of sizers, endoscopic decalcification instruments, second-generation sutureless valves and aortic closure devices in order to target a 4-step, quick, minimally traumatic treatment of the stenosed aortic valve.

**Endoscopic sizers**

Aortic intraoperative sizing is limited for endoscopic surgery using existing sizers. The existing sizers are rigid and incompressible, with only small diameter sizers (19 or 21 mm) that can enter the cutaneous orifice of 20 mm of the main thoracoscopic trocar without requiring skin enlargement, and without conflict with the margin of the ribs. Secondly, the holder of an ideal sizer should be malleable to facilitate a perfect alignment with the central line of the aortic root when the position of the trocars is not perfectly axed.

From a theoretical standpoint, sizing could be exclusively image based as described in the initial experience. However, the annulus elasticity should be considered in sizing for a sutureless valve implant, irrespective of the surgical access. The diameter of the sutureless valve should ideally be selected using a sizer that can provide an immediate feedback force to the operator to help assess the adequate “internal diameter/resistance to radial expansion” ratio and thereby select the most appropriate size. Also, such a sizer should be progressive in order to cover the measurement of intermediate sizes of the prosthesis (20, 22, 24, 26 mm) that are not always provided by industry calibrators. We have recently developed and patented a prototype, however this is yet to be used in clinical practice (*Figure 3A,B*).

**Decalcifiers**

A dedicated instrument for decalcification is not currently available; nor are minimally invasive aortic instruments. The ideal endoscopic decalcification instrument should enable rapid and safe valve decalcification without embolization and avoid repeated insertion and extraction of the device through the aortic root.

**Second-generation sutureless valves**

First-generation sutureless valves have been conceived for open surgery and not for TEAVR. We have evaluated the ratio of compression of the 3f Enable and Perceval valves: the 3f Enable valve is available in sizes from 19 to 27 mm requires a 20 mm trocar to be inserted in the thorax; only the small size of the Perceval model fits a 15 mm trocar (*Figure 3C*). A 20 mm trocar is necessary for the other sizes. The Edwards Intuity model (Edwards, Irvine, CA, USA) is composed by a Magna incompressible bioprosthesis and does not fit trocars.

Second generation sutureless valves should ideally allow the use of lower diameter trocars. The mechanism of delivery should be easy and intuitive for TEAVR approach. Use of percutaneous valves could be considered with this objective. However, concerns have been raised regarding the lack of grip once the native calcium is ablated and the potential lesions that the radial force of those valves could cause on a decalcified annulus.

---

*Figure 3* (A) Endoscopic feedback force sutureless sizer (prototype, undeployed position); (B) endoscopic feedback force sutureless sizer (prototype, deployed position); (C) a small size Perceval bioprosthesis fitting a 15 mm trocar.
In our initial TEAVR experience, we selected the 3f Enable valve because of the previous experience with this valve in our department. We are now proceeding to cadaver TEAVR with the balloon expandable Sorin Perceval (Sorin Biomedica Cardio Srl, Saluggia, Italy) model, which seems to have a shorter learning curve. However, adjustments in case of malposition appear less possible.

**Aortic closure device**

Aortic closure devices are also needed, as aortic closure remains a challenge in endoscopic procedures. The EWAC1000 suturing device (Edwards, Irvine, CA, USA) was tested on cadavers, without a time advantage over conventional suturing. A learning curve effect cannot be excluded. The articulated arm seems to be too long to easily move in a reduced working space compared with left atrium closure during minimally invasive mitral surgery. Robotic technology appears promising in speeding aortic closure, however this approach has not yet been tested in our anatomy laboratory.

**Conclusions**

The totally endoscopic aortic valve replacement has proven to be technically feasible with the current technology in selected patients. However, it is far from being a mature technique as indicated by operative times. Potential evolution towards a reproducible, quick and safe procedure relies on the development of specifically adjuvant devices.

**Acknowledgements**

*Disclosure:* The authors declare no conflict of interest.

**References**